Clinical trials: Circulating Tumor DNA
Colon Adenocarcinoma, High-Frequency Microsatellite Instability
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
This phase Ib/II trial studies how well anti-PD-L1/TGFbetaRII fusion protein M7824 (M7824) works in treating patients with colorectal cancer (or with other solid tumors with microsatellite instability) that has spread to other…
- Conditions
- Colon Adenocarcinoma, High-Frequency Microsatellite Instability, Metastatic Malignant Solid Neoplasm, Rectal Adenocarcinoma
- Trial name
- NCT03436563
- Testing
- Anti-PD-L1/TGFbetaRII Fusion Protein M7824
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery.
- Trial name
- NCT04068103
- Testing
- Capecitabine, Fluorouracil, Leucovorin
- Where
- 957 sites in United States, Canada and 1 more
- Volunteers
- 635 people
- Sponsor
- NRG Oncology
Breast Cancer, Triple Negative Breast Cancer
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms based on plasma ctDNA positivity and genomic marker(s).
- Trial name
- PERSEVERE (NCT04849364)
- Testing
- Capecitabine, Talazoparib, Pembrolizumab
- Where
- 13 sites in United States
- Volunteers
- 52 people
- Sponsor
- Bryan Schneider, MD
Colorectal Neoplasms, Trifluridine and Tipiracil
Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection
This trial is a randomized, double-blind, multinational Phase III study to evaluate the efficacy and safety of preemptive treatment with FTD/TPI compared with administration of placebo as follow-up, which is the standard of care…
- Conditions
- Colorectal Neoplasms, Trifluridine and Tipiracil, Circulating Tumor DNA
- Trial name
- ALTAIR (NCT04457297)
- Testing
- trifluridine and tipiracil
- Where
- 39 sites in Japan, Taiwan
- Volunteers
- 243 people
- Sponsor
- National Cancer Center Hospital East
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
This phase II trial studies how well letrozole, anastrozole, or fulvestrant work when given together with ribociclib, palbociclib, and/or abemaciclib in treating patients with hormone receptor (HR) positive breast cancer that has…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT04256941
- Testing
- Abemaciclib, Anastrozole, Fulvestrant
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Squamous Cell, Head and Neck Neoplasms
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
The primary objective of this study is to evaluate whether genomic based risk-stratification can be used in deciding whether to de-intensify in patients with Human Papillomavirus (HPV)-associated Oropharyngeal Squamous Cell…
- Conditions
- Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
- Trial name
- NCT03077243
- Testing
- Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation
- Where
- 4 sites in United States
- Volunteers
- 195 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics
Immune Evasion, Tumor, Neoplastic Cells, Circulating
Immune Mechanisms After Radiofrequency Ablation of Pulmonary Metastases From Colorectal Cancer Origin
Local percutaneous thermal ablation is frequently proposed in the management of metastatic diseases. Radiofrequency ablation (RFA) has demonstrated good results when the metastatic disease is limited and slowly evolving.
- Conditions
- Immune Evasion, Tumor, Neoplastic Cells, Circulating, Circulating Tumor Cell, Pulmonary Metastasis
- Trial name
- ARFIM (NCT03960021)
- Testing
- RFA interventions
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Institut Bergonié
Prostate Cancer, Metastasis
Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.
This multi-center, phase II trial will be conducted in men with castration resistant prostate cancer. The aim of the TRAP trial is to test whether a new precise radiotherapy technique called stereotactic body radiotherapy (SBRT)…
- Conditions
- Prostate Cancer, Metastasis, Toxicity Due to Radiotherapy, Circulating Tumour DNA
- Trial name
- TRAP (NCT03644303)
- Testing
- SBRT + ADT
- Where
- 7 sites in United Kingdom
- Volunteers
- 86 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Esophagogastric Tumors, Gastric Cancer
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
The purpose of this study is to find out whether treatment with trastuzumab combined with pembrolizumab will improve the clearance of tumor DNA from participants' bodies after surgery.
- Conditions
- Esophagogastric Tumors, Gastric Cancer, Gastric Tumor, Esophageal Cancer
- Trial name
- NCT04510285
- Testing
- Trastuzumab, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 1 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma
HCC Screening Using DNA Methylation Changes in ctDNA
Hepatocellular Carcinoma (HCC) is the fifth most common cancer world-wide. It is particularly prevalent in Asia, and its occurrence is highest in areas where hepatitis B is prevalent, indicating a possible causal relationship.
- Trial name
- NCT03483922
- Testing
- ctDNA methylation in and it's Correlation wth Development and prediction of HCC
- Where
- Bangladesh
- Volunteers
- 403 people
- Sponsor
- HKGepitherapeutics
Ovarian Carcinoma, Soft Tissue Sarcoma
Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
A phase Ib trial study of trabectedin when prescribed in combination with durvalumab in locally advanced/unresectable soft-tissue sarcoma and ovarian carcinomas.
- Trial name
- TRAMUNE (NCT03085225)
- Testing
- Combination of trabectedin with durvalumab
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Institut Bergonié
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
This phase II trial studies how well pembrolizumab works in treating patients with non-squamous non-small cell lung cancer which has spread to other places in the body.
- Trial name
- NCT02955758
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Joel Neal
Lymphoma
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
This Phase II, open-label, multicenter study will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone…
- Trial name
- NCT04980222
- Testing
- Glofitamab, Tocilizumab, Doxorubicin
- Where
- 20 sites in United States, Denmark and 4 more
- Volunteers
- 46 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer Metastatic
T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
The purpose of this study is to compare the frequency and abundance of T790M mutation among the different Clinical modes of EGFR-TKI failure.
- Trial name
- NCT02418234
- Testing
- mutation detection, ARMS and ddPCR, ctDNA analysis
- Where
- China
- Volunteers
- 314 people
- Sponsor
- First People's Hospital of Hangzhou
Neoplasms, Breast
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast cancer (Independent of hormone receptor [HR] status, including HR positive [+] and…
- Trial name
- ZEST (NCT04915755)
- Testing
- Niraparib
- Where
- 198 sites in United States, Argentina and 25 more
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Metastatic Breast Cancer
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
To assess longitudinal changes in allele frequency of ESR1 mutation in plasma in patients treated with Fulvestrant plus palbociclib compared to tamoxifen plus palbociclib
- Trial name
- NCT02913430
- Testing
- Fulvestrant, Tamoxifen, Palbociclib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Shannon Puhalla